Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA

The meta-regression did indicate, however, that endothelial function measurement technique made a significant contribution to heterogeneity. In fact, a pooled analysis under the mixed-effects model suggested that 40.5% of the total amount of heterogeneity could be accounted for by including endothelial function technique as a moderator in the model. Nevertheless, despite the heterogeneity of the publication, the results from the meta-analysis do raise the possibility that certain subsets of patients may benefit from treatment more than others. In this way, the new review contrasts with previous reviews, which did not find an effect of anti-TNFα molecules on measures of arterial stiffness and endothelial dysfunction.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Ursini F, Leporini C, Bene F, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017 Jul 13;7(1):5346. doi: 10.1038/s41598-017-05759-2.

Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

Long-term use of TNFα inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis is associated with both gains in fat mass and a shift in fat mass to the visceral region. (posted Jan. 14)

New Treatments Needed to Prevent Fractures in Osteoporosis

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

JAK Inhibitors: Are All Promises Fulfilled?

Does Anti-Tumor Necrosis Factor-Alpha Increase Cardiovascular Burden?

Related Articles